Insulet Corporation · NASDAQ:PODD
Insulet — J.P. Morgan Healthcare Conference 2024
15 slides from Insulet's conference presentation, Jan 9, 2024
Slide 1: Insulet Corporation – J.P. Morgan Healthcare Conference
Insulet Corporation J.P. Morgan Healthcare Conference Kimsue Podder since 2023 Jim Hollingshead, Ph.D., President & Chief Executive Officer January 9, 2024
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on current expectations and beliefs concerning future developments a
Slide 3: Driving Continued Growth and Success
Driving Continued Growth and Success 1 Achieving our mission with market-leading innovation 2 Strong fundamentals powering financial results 3 Penetrating and leading in the diabetes market Eloise Podder 4 Realizing the Omnipod 5 opportunity since 2023 3
Slide 4: Achieving Our Mission with Market-Leading Innovation
Achieving Our Mission with Market-Leading Innovation Simplify Life for People with Diabetes Market-Leading • Omnipod platform Technology • Reduce burden • Improve outcomes Market-Leading Competitive Advantages Revenue Growth • Skilled talent with deep in-house expertise • Robust innovation roadmap •
Slide 5: Strong Fundamentals Powering Financial Results
Strong Fundamentals Powering Financial Results Maximizing Investing Expanding Revenue for Growth Operating Margins ~24% ~19% +~11pts Revenue CAGR R&D Expense CAGR Adjusted Operating Margin 2018 - 20231 2017 - 2022 2017 - 20222 Powered by Omnipod 5, the Most Prescribed AID3 System in 2023 in the U.S.
Slide 6: Well-Positioned for the Massive Market Opportunity
Well-Positioned for the Massive Market Opportunity 537M 1.3B 2022 2050 People with Diabetes Worldwide1,2 ~64M Requiring Insulin Worldwide1 ~11M3 Total Addressable Market3 45% 55% Type 1 Insulin Intensive Type 2 +3M U.S. Basal Opportunity (Future TAM opportunity) 1. Source: IDF Atlas 10th Edition. 2.
Slide 7: Omnipod is Unlocking the Largest Market Opportunity
Omnipod is Unlocking the Largest Market Opportunity “Omnipod has been a game changer! No Conventional Multiple Daily VS. more multiple Insulin Pump Injections (MDI) daily injections!” –Ximena’s Mom ~5% ~95% Ximena Podder since 2023 of the global market of the global market One pod replaces opportuni
Slide 8: Winning on All Dimensions with Omnipod 5
Winning on All Dimensions with Omnipod 5 The Omnipod Platform + Omnipod 5 with AID = Obvious • No needles or tubes • Cutting-edge algorithm using micro-dose technology Choice • Discreet, wearable, disposable • Industry-leading time in range • Pay-as-you-go economics for customers and payors • Very f
Slide 9: Omnipod 5 Simplifies Diabetes Management
Omnipod 5 Simplifies Diabetes Management SIMPLICITY MEETS OUTCOMES Driving Outcomes Automated, continuous glucose monitoring (CGM) integration World-Class User Experience Tubeless, smart-phone controlled, simple interface Data & Connectivity Always cloud connected PIPELINE Advanced Performance with
Slide 10: Building a Full Range of Type 2 Diabetes Options
Building a Full Range of Type 2 Diabetes Options – Omnipod is the Clear Choice PATIENT JOURNEY AID New Market Omnipod GO to deliver daily basal insulin Feature Set … or Omnipod 5 to better manage disease As insulin needs progress, (Future state1) customers move downstream Basal Rate Only to either O
Slide 11: Innovation Drives Horizons of Growth
Innovation Drives Horizons of Growth Lead the Industry with Novel Innovations Expand TAM Drive Omnipod 5 Growth • Continually improve customer experience and ease of use • Innovate and expand product indications and global presence • Next-generation algorithms • Expand the Omnipod 5 platform • Omnip
Slide 12: Driving Continued Growth and Success
Driving Continued Growth and Success 1 Achieving our mission with market-leading innovation 2 Strong fundamentals powering financial results 3 Penetrating and leading in the diabetes market Holly Podder 4 Realizing the Omnipod 5 opportunity since 2017 12
Slide 13: Thank You
Thank You Insulet
Slide 14: Appendix
Appendix Insulet
Slide 15: Reconciliation of Non-GAAP Measures Operating Margin
Reconciliation of Non-GAAP Measures Operating Margin Year Ended December 31, 2022 (dollars in millions) Operating Income Revenue Percent of Revenue GAAP $37.6 $1,305.3 2.9% Voluntary medical device corrections1 57.9 Legal costs2 25.2 CEO transition costs3 3.4 Non-GAAP $124.1 $1,305.3 9.5% The Compan